Sanofi News and Global Healthcare & Pharmaceutical Innovation Updates
85.95
0.1900
0.22 %
At close
11/10
EUR
Daily range
84.39
86.10
86.10
Weekly range
81.05
86.10
86.10
Sanofi raises 2026 sales outlook, weighs larger M&A in drug pipeline push
Sanofi is lifting its 2026 growth targets as demand for its asthma blockbuster Dupixent continues to support performance. The upgraded guidance comes as the French drugmaker also signals a greater ...
Sanofi faces pressure to rebuild drug pipeline as Dupixent patent risk nears
Sanofi is under mounting pressure to find new sources of growth as its top-selling drug Dupixent moves closer to losing patent protection in the early 2030s. Chief executive Belén Garijo is ...
Sanofi avoids EU fine over rival flu vaccine marketing case
EU antitrust regulators are closing a case against Sanofi after the French drugmaker offers commitments tied to how it markets its flu vaccine in France and Germany. The move spares the company ...
What's behind Sanofi's latest 5.4% stock pullback?
Sanofi (SNY) dropped 5.37% after investors reacted negatively to asset impairments and pipeline changes, even as the company reported strong first-half results and raised its 2026 sales and ...
U.S. biotech outlook improves as FDA review stance turns more supportive
Leadership changes at the FDA are starting to reshape sentiment across U.S. biotech after a period of regulatory volatility that erased billions in sector value. A more predictable review approach ...
Sanofi stock slides as price lingers below the long-term average
Sanofi (SNY) stock is trading at $42.66, marking a daily decline of 1.77%. The session ended near today's low, and SNY is currently positioned below its short-term ...
European Commission opens antitrust probe into Sanofi flu vaccine promotion
EU regulators are escalating scrutiny of competition in the vaccines market by formally examining Sanofi's promotion of its enhanced flu shot for older adults. The case focuses on whether ...
U.S. drugmakers deepen China biotech partnerships as security scrutiny grows
U.S. and European pharmaceutical groups are expanding licensing and development ties with Chinese biotech companies as patent expirations pressure them to replenish drug pipelines. That shift is ...
